(Q38218848)

31 August 2017

title

MGMT testing--the challenges for biomarker-based glioma treatment (English)

1 reference

31 August 2017

0 references

6

Andreas von Deimling

0 references

Michael Weller

2

object named as

Michael Weller

1 reference

31 August 2017

1

Wolfgang Wick

1 reference

31 August 2017

10

Guido Reifenberger

1 reference

31 August 2017

8

Monika Hegi

1 reference

31 August 2017

7

Christoph Plass

1 reference

31 August 2017

Martin J van den Bent

3

object named as

Martin van den Bent

1 reference

31 August 2017

Marc Sanson

4

1 reference

31 August 2017

Markus Weiler

5

1 reference

31 August 2017

Michael Platten

9

1 reference

31 August 2017

language of work or name

English

0 references

publication date

10 June 2014

1 reference

31 August 2017

published in

Nature Reviews Neurology

1 reference

31 August 2017

volume

10

1 reference

31 August 2017

issue

7

1 reference

31 August 2017

page(s)

372-385

1 reference

Adult glioma incidence trends in the United States, 1977-2000.

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Malignant gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

A randomized trial of bevacizumab for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Phase II study of protracted daily temozolomide for low-grade gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Self-destruction and tolerance in resistance of mammalian cells to alkylation damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Targeted modulation of MGMT: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Novel mechanism whereby nuclear factor kappaB mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Regulation of the human O(6)-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Interaction of hypoxia-inducible factor-1α and Notch signaling regulates medulloblastoma precursor proliferation and fate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

MiR-221/222 target the DNA methyltransferase MGMT in glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Mutator pathways unleashed by epigenetic silencing in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Both base excision repair and O6-methylguanine-DNA methyltransferase protect against methylation-induced colon carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Tumor-associated mutations in O⁶ -methylguanine DNA-methyltransferase (MGMT) reduce DNA repair functionality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

DNA methylation biomarkers in cancer: progress towards clinical implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Prevention of PCR cross-contamination by UNG treatment of bisulfite-treated DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase π in glioblastoma and the survival of the patients treated with nimustine hydrochloride: An immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

O6-methylguanine-DNA methyltransferase activity in breast and brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

European consensus conference for external quality assessment in molecular pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

External quality assessment of BRAF molecular analysis in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Interlaboratory comparison of IDH mutation detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Assessing and comparing the performance of molecular diagnostic tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

The somatic genomic landscape of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

A prospective study on glioblastoma in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

A sequencing method based on real-time pyrophosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

Reporting recommendations for tumor marker prognostic studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2014.100

O6-benzylguanine and its role in chemotherapy.

31 March 2020

1 reference

12 December 2020

Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma.

1 reference

12 December 2020

Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene

1 reference

12 December 2020

Regulation of expression of the DNA repair gene O6-methylguanine-DNA methyltransferase via protein kinase C-mediated signaling

1 reference

12 December 2020

Genomic instability and tolerance to alkylating agents.

1 reference

12 December 2020

10.1038/NRNEUROL.2014.100

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1050569836

0 references

1 reference